StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
OCUL

Ocular Therapeutix, Inc.

OCUL Nasdaq Pharmaceutical Preparations EDGAR ↗
$7.87
+0.21 +2.81%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$1.73B
Revenue (TTM) ⓘ
$52.1M
Net income (TTM) ⓘ
-$301M
EPS (TTM) ⓘ
$-1.40
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
-$217M
Cash ⓘ
$599M
Total assets ⓘ
$671M
Gross margin ⓘ
—
52-week range ⓘ
$6.23 – $16.44

AI briefing

from the latest 10-K, 10-Q and 8-K events

Ocular Therapeutix is an integrated biopharmaceutical company focused on developing and commercializing hydrogel-based therapies for retinal and other eye diseases, with a lead candidate in Phase 3 for wet AMD.

What they do

Ocular Therapeutix develops and commercializes products using its proprietary ELUTYX bioresorbable hydrogel technology. Its only marketed product, DEXTENZA, is an FDA-approved intracanalicular insert for ocular inflammation, pain, and itching. The lead pipeline candidate, AXPAXLI (OTX-TKI), is an intravitreal axitinib hydrogel in Phase 3 registrational trials for wet AMD and diabetic retinal disease; OTX-TIC, a travoprost intracameral hydrogel for glaucoma, has completed Phase 2.

Revenue drivers

  • DEXTENZA — The sole commercial product, an FDA-approved corticosteroid insert for post-surgical ocular inflammation/pain and allergic conjunctivitis itching. Its contribution to total revenue is not broken out in the provided excerpts.
  • Axitinib (AXPAXLI) milestones — No revenue yet; potential future value depends on NDA approval and launch. Pipeline progress and regulatory milestones are key value drivers.
  • Total product revenue — Annual revenue increased from $43.5M in 2021 to $63.7M in 2024, then declined to $52.0M in 2025; quarterly revenue ranged from $10.8M to $14.5M in 2025-2026.

Recent performance

In Q2 2026, revenue was $13.5M, up from $10.8M in Q1 2026 but roughly flat versus Q2 2025 (not specified). Net loss for 2025 was $265.9M, wider than the $193.5M loss in 2024; operating cash flow was negative $204.9M in 2025. The balance sheet at June 30, 2026 showed cash of $598.6M and total assets of $671.3M. SOL-1 Week 52 data, announced in February 2026, met the primary endpoint with statistical significance.

Strategy

The company is advancing AXPAXLI toward a Q4 2026 NDA submission for wet AMD, using the 505(b)(2) pathway to potentially shorten FDA review by up to 60 days. It plans to support the NDA with SOL-1 efficacy/safety data, an interim safety analysis from SOL-R, and axitinib's established profile. Management is accelerating commercial readiness ahead of a potential 2027 launch and expects cash runway into 2028. The company is evaluating next steps for OTX-TIC and continues to leverage DEXTENZA's commercial experience.

Risks

  • Regulatory delay — NDA submission and FDA review could be delayed if the pre-NDA meeting or interim SOL-R safety analysis reveal issues.
  • Clinical failure — AXPAXLI is the lead asset; if SOL-R or confirmatory evidence fails to meet safety or efficacy requirements, the program could be set back.
  • Commercial execution — As a company with only one approved product, launch success for AXPAXLI depends on market acceptance, reimbursement, and competition from established anti-VEGF therapies.
  • Cash burn — Operating cash flow was negative $204.9M in 2025; despite $598.6M cash, continued losses require significant capital to fund operations beyond 2028.

Outlook

Management plans to file the AXPAXLI NDA for wet AMD in Q4 2026, following a pre-NDA meeting in Q3 2026 and an interim SOL-R safety analysis. They expect to utilize the 505(b)(2) pathway to potentially shorten the FDA review timeline by up to 60 days. A potential U.S. launch is targeted for 2027, with cash runway into 2028.

Recent SEC filings

40 most recent
Annual, quarterly & current reports